Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Flagstar Bank NA (FLG) Price & Performance

Amylx Pharmaceuticals IncTrade
Flagstar Bank NATrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Flagstar Bank NA — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Flagstar Bank NA trades at $14.21 (market cap $5.82B). The key difference: Flagstar Bank NA is far larger — about 2.3× Amylx Pharmaceuticals Inc's market cap, and Flagstar Bank NA pays a 0.29% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXFLG
Market Cap
$2.53B$5.82B
Sector
HealthFinancials
52-Week High
$24.19$15.36
52-Week Low
$7.82$10.72
Enterprise Value
$2.28B
Dividend Yield
0.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Flagstar Bank NA

Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.

The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG